Literature DB >> 16493256

Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients.

Anne E Kayl1, Christina A Meyers.   

Abstract

PURPOSE OF REVIEW: Women diagnosed with ovarian cancer or breast cancer often face aggressive chemotherapy involving multiple treatment regimens. These treatments may be associated with significant side-effects that adversely impact patient quality of life. In this review, we will highlight recent research on side-effects of chemotherapy and the quality-of-life concerns of women with ovarian and breast cancer. RECENT
FINDINGS: Adjuvant chemotherapy has demonstrated efficacy in the management of ovarian and breast cancers. In addition to physical side-effects, a subset of women receiving chemotherapy will experience significant cognitive dysfunction that adversely affects their perceived quality of life. Variables including disease response, treatment indication and extent of the patient's social support also influence quality-of-life ratings.
SUMMARY: Although prolongation of survival remains the primary goal of chemotherapy, the palliation of symptoms and preservation of quality of life are also important treatment considerations. Chemotherapy may be associated with nausea, vomiting, hair loss, cognitive dysfunction, fatigue, changes in sexual functioning and reductions in quality-of-life ratings. Although rare to date, prospective, randomized, longitudinal studies that incorporate a pre-treatment assessment of symptom burden and perceived quality of life are necessary to define the severity and pattern of treatment-related change and subsequently guide intervention strategies. In some cases, quality-of-life issues may help to guide patient-care decisions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493256     DOI: 10.1097/01.gco.0000192996.20040.24

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  47 in total

1.  What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer.

Authors:  Meagan S Whisenant; Faith A Strunk; Debasish Tripathy; Loretta A Williams
Journal:  Support Care Cancer       Date:  2019-04-02       Impact factor: 3.603

2.  Symptom Care at Home: A Comprehensive and Pragmatic PRO System Approach to Improve Cancer Symptom Care.

Authors:  Kathi Mooney; Meagan S Whisenant; Susan L Beck
Journal:  Med Care       Date:  2019-05       Impact factor: 2.983

3.  Continuous, objective measurement of physical activity during chemotherapy for breast cancer: the Activity in Treatment pilot study.

Authors:  Sandahl H Nelson; Lauren S Weiner; Loki Natarajan; Barbara A Parker; Ruth E Patterson; Sheri J Hartman
Journal:  Transl Behav Med       Date:  2020-10-08       Impact factor: 3.046

4.  Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study.

Authors:  D D Correa; J C Root; M Kryza-Lacombe; M Mehta; S Karimi; M L Hensley; N Relkin
Journal:  Brain Imaging Behav       Date:  2017-12       Impact factor: 3.978

5.  The experience of cancer survivors in community-based psycho-social support activities in Shanghai, China: a qualitative study.

Authors:  Ji-Wei Wang; Tian-Rui Zhang; Qian Shen; Zhi-Qi Yang; Cong Liu; Si-Jia Chen; Jiang Li; Zheng-Nian Luo; Zheng-Ping Yuan; Jin-Ming Yu
Journal:  Qual Life Res       Date:  2015-06-21       Impact factor: 4.147

6.  Cognitive dysfunction in cancer patients: an educational needs area improved by a single intervention.

Authors:  Irene Perez Vetto; John T Vetto
Journal:  J Cancer Educ       Date:  2007       Impact factor: 2.037

7.  Sustainable impact of an individualized exercise program on physical activity level and fatigue syndrome on breast cancer patients in two German rehabilitation centers.

Authors:  Freerk T Baumann; Oliver Bieck; Max Oberste; Rafaela Kuhn; Joachim Schmitt; Steffen Wentrock; Eva Zopf; Wilhelm Bloch; Klaus Schüle; Monika Reuss-Borst
Journal:  Support Care Cancer       Date:  2016-12-09       Impact factor: 3.603

8.  A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).

Authors:  Janet M Schloss; Maree Colosimo; Caroline Airey; Paul Masci; Anthony W Linnane; Luis Vitetta
Journal:  Support Care Cancer       Date:  2016-09-09       Impact factor: 3.603

9.  Delayed emotional recovery after taxane-based chemotherapy.

Authors:  Lisa M Thornton; William E Carson; Charles L Shapiro; William B Farrar; Barbara L Andersen
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

10.  Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.

Authors:  Nissar A Darmani; Jano J Janoyan; Jennifer Crim; Juan Ramirez
Journal:  Eur J Pharmacol       Date:  2007-02-16       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.